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Abstract
Background: Multiple lines of evidence have suggested that valproic acid (VPA) might benefit patients with spinal muscular
atrophy (SMA). The SMA CARNIVAL TRIAL was a two part prospective trial to evaluate oral VPA and l-carnitine in SMA
children. Part 1 targeted non-ambulatory children ages 2–8 in a 12 month cross over design. We report here Part 2, a twelve
month prospective, open-label trial of VPA and L-carnitine in ambulatory SMA children.
Methods: This study involved 33 genetically proven type 3 SMA subjects ages 3–17 years. Subjects underwent two baseline
assessments over 4–6 weeks and then were placed on VPA and L-carnitine for 12 months. Assessments were performed at
baseline, 3, 6 and 12 months. Primary outcomes included safety, adverse events and the change at 6 and 12 months in
motor function assessed using the Modified Hammersmith Functional Motor Scale Extend (MHFMS-Extend), timed motor
tests and fine motor modules. Secondary outcomes included changes in ulnar compound muscle action potential
amplitudes (CMAP), handheld dynamometry, pulmonary function, and Pediatric Quality of Life Inventory scores.
Results: Twenty-eight subjects completed the study. VPA and carnitine were generally well tolerated. Although adverse
events occurred in 85% of subjects, they were usually mild and transient. Weight gain of 20% above body weight occurred
in 17% of subjects. There was no significant change in any primary outcome at six or 12 months. Some pulmonary function
measures showed improvement at one year as expected with normal growth. CMAP significantly improved suggesting a
modest biologic effect not clinically meaningful.
Conclusions: This study, coupled with the CARNIVAL Part 1 study, indicate that VPA is not effective in improving strength or
function in SMA children. The outcomes used in this study are feasible and reliable, and can be employed in future trials in
SMA.
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Spinal muscular atrophy (SMA) is an autosomal recessive motor
neuron disease that affects approximately 1 in 8,000 newborns. It
is a leading cause of infant and childhood morbidity [1–6]. The
genetics of SMA are complex, but all patients have homozygous
mutations in exon 7 of the survival of motor neuron (SMN1) gene
on chromosome 5q13 [7,8]. These mutations result in decreased
expression of SMN protein, which functions chiefly as part of a
complex (the SMN complex) that plays a crucial role in eukaryotic
mRNA processing [9–11]. SMN protein is also transported in the
axon, where it appears to play an important role in neuromuscular
junction formation and axonal growth. The relative contribution
of these functions to the pathogenesis of SMA is still unclear and a
matter of some debate [11].
A feature that makes SMA unique among human genetic
diseases is that a genomic duplication at the SMN locus has
resulted in a nearly identical gene, SMN2 that lies centromeric
to the SMN1 gene and differs from SMN1 mainly by a single C
to T nucleotide substitution at the splice junction of exon 7. This
mutation does not affect the amino acid sequence, but does alter
mRNA splicing in favor of transcripts lacking exon 7 [12–17]. A
small amount of full-length SMN transcript is produced by the
SMN2 gene, however, and SMN2 copy number is a major
determinant of phenotype [11,18,19]. Babies with severe SMA
have fewer copies of SMN2 than those with milder forms of the
disease and mouse models of SMA recapitulate this protective
effect of SMN2 copy number on phenotypic severity [9–18].
These findings suggest the possibility that pharmacologic or
genetic strategies to increase production of full-length transcript
from SMN2 might prove to be an effective therapeutic strategy
in SMA.
Valproic acid (VPA) increases SMN expression in SMA patient-
derived cell lines as well as in SMA patients probably through its
action as a histone deacetylase (HDAC) inhibitor [20–26]. VPA
has also been shown to improve gross motor function and increase
Figure 1. Inclusion/exclusion criteria for study enrollment.
doi:10.1371/journal.pone.0021296.g001
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VPA treatment also resulted in larger evoked motor potentials on
electrophysiologic studies, less degeneration of spinal motor
neurons and improved neuromuscular junction innervation [28].
In addition, three open label trials of VPA in humans all suggested
a benefit in strength, motor function, or both [29–31]. These
encouraging results led us to perform a comprehensive clinical trial
of VPA in a large cohort of children with SMA. Because VPA can
deplete carnitine stores that are already diminished in SMA
patients by low muscle mass, we chose a combined regimen of
VPA and carnitine for this study [31,32]. Part 1 of this trial was a
double blind, randomized, intention to treat trial of VPA and
carnitine in non-ambulatory SMA patients (CARNI-VAL Part 1)
that has previously been reported [32]. We report here the results
of CARNI-VAL Part 2, an open-label, single arm trial of VPA and
carnitine in ambulatory children with SMA.
Methods
Trial Design
The SMA CARNI-VAL trial was a multi-center phase 2 trial of
VPA and carnitine in patients with spinal muscular atrophy. The
primary objective was to assess the safety, tolerability, and efficacy
of a combined regimen of oral VPA and carnitine in SMA patients
2–17 years of age. Secondary objectives were to refine electro-
physiological and clinical techniques to better follow the course of
ambulatory patients with SMA, in which clinical outcome
measures have not been extensively validated. The protocol for
this trial and supporting CONSORT checklist are available as
supporting information; see Checklist S1 and Protocol S1.
The trial consisted of two parallel multi-center studies, targeting
different SMA populations (Clinicaltrials.gov ID NCT00227266)
[32]. Part 2 described here was a parallel single-armed, open-label
Figure 2. Consort flow sheet.
doi:10.1371/journal.pone.0021296.g002
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This open-label trial design was chosen as an initial study for two
reasons. First, previous positive studies were small and largely
anecdotal in nature, and quality natural history outcomes that
could be used to establish power in a randomized clinical trial
were lacking. Second, given the availability of VPA and previously
reported anecdotal ‘‘positive’’ trials, enthusiasm for a placebo-
controlled trial in the relatively small ambulatory SMA community
was limited, suggesting that recruitment for a controlled study
would likely be extremely difficult. Under these circumstances, we
felt that an open label study with objective outcome measures and
adverse event ascertainment would improve on the information
available and could be completed in a reasonable time frame, with
the potential for identifying a possible signal which could be
valuable in design of future clinical trials.
Study population
We prospectively enrolled 33 ambulatory SMA children at six
centers in North America following the inclusion and exclusion
criteria outlined in Figure 1. This sample size was chosen to
accommodate an expected 20% drop out rate and thus provide at
least 25 patients completing the study. This sample size provided a
95% confidence interval that would be no wider than plus or
minus 40% of the standard deviation around the mean for each
functional motor scale measure. The study was approved by the
Institutional Review Board (IRB) at each participating clinical trial
site (University of Wisconsin-Madison Health Sciences; Wayne
State University; Ohio State University; Johns Hopkins University,
Centre Hospitalier Universitaire Sainte-Justine, Universite de
Montreal, and the University of Utah, the central coordinating
site. Written informed parental consent (subjects ,18 years) and
assent (subjects $7 years) were obtained for all subjects. The
progress of all participants through the trial for both studies is
diagrammed in Figure 2.
Study procedures
All subjects completed two baseline visits within a six week
period to assure that the examiners’ methodologies were reliable
and that subjects enrolled in the study exhibited test-retest stability
prior to the start of the trial. Having two baseline measures also
allowed younger subjects to acclimate to testing procedures.
Following the second visit, all subjects were placed on VPA and
carnitine. All subjects received active treatment for a full 12
months. VPA was provided by Abbott Pharmaceutical as 125 mg
divalproex sodium coated particles (DepakoteH sprinkle capsules)
and L-carnitine was provided by Sigma-Tau Pharmaceutical in a
100 mg/ml liquid (CarnitorH). Divalproex sodium was adminis-
tered in divided doses two to three times daily to maintain trough
levels of 50–100 mg/dL. L-carnitine was dosed at 50 mg/kg/day
to a maximum of 1000 mg, divided into two daily doses. Study
compliance was assessed through pill counts at each visit with
appropriate dosing at least 80% of the time by pill count
considered compliance. Compliance was further assessed through
trough VPA levels.
Treatment assessments were performed at 3 (V1), 6 (V2) and 12
(V3) months. Safety laboratory studies were performed at baseline,
2–3 weeks following initiation, at each treatment visit and midway
between V2 and V3 visits, and included a basic chemistry profile,
complete blood count with platelets, transaminases, carnitine
profile, amylase, lipase and trough VPA levels. A central medical
monitor reviewed all subjects’ blood tests and adverse events and
performed dosing adjustments or additional testing where
necessary. Adverse events were graded using Common Terminol-
ogy Criteria for Adverse Events v3.0 (CTCAE v3.0). An
independent Data and Safety Monitoring Committee provided
oversight for the study and performed interim safety data analyses,
and had the ability to stop the study if there was a safety concern.
Outcome measures
Primary outcome measures included laboratory safety and
adverse event data, as well as efficacy as measured by change from
baseline at 6 and 12 months in the Modified Hammersmith
Functional Motor Scale-Extend (MHFMS-Extend), timed tests of
function (TTF) and fine motor modules (FMM). The MHFMS-
Extend includes the 20 items in the original MHFMS, as well as an
additional eight items in a Gross Motor Module (GMM). Details of
this testing and the appropriate protocols are available at http://
smaoutcomes.org [33]. For statistical purposes, each component of
the testing was analyzed individually as discussed below.
Secondary outcome measures, as in the Part 1 study, included
maximum ulnar compound muscle action potential (CMAP)
amplitude as an estimate of innervation, dual-energy X-ray
absorptiometry (DEXA) evaluation of body composition and bone
density, quantitative assessment of SMN mRNA; evaluation of
quality of life using the Pediatric Quality of Life Inventory
(PedsQL
TM) and for children .5 years, change from baseline
measures of pulmonary function and muscle strength via handheld
myometry at 6 and 12 months [31,32]. The protocol for ulnar
CMAP amplitude determination has been previously described
and is available at http://smaoutcomes.org. Dual-energy X-ray
absorptiometry (DEXA) scanning for bone density and body
composition was performed at the Columbus, Salt Lake City, and
Madison sites using the Norland DEXA XR-36 software version
3.3.1 for small subjects. Relative quantification of full-length
(flSMN) and exon 7-lacking (D7 SMN) SMN transcripts in whole
blood was performed as previously described [32]. Results are
reported as relative amounts of flSMN or D7 SMN normalized
against RPLPO (large ribosomal protein). Quality of life (QOL)
was assessed using the 0–100 scale (PedsQL
TM) [34]. The same
parent completed the (PedsQL
TM) at each visit and children .5
years of age completed the age-appropriate (PedsQL
TM). A
change of 4.4 in the child self-report and 4.5 in the parent-proxy
report was considered a meaningful difference in this instrument
Table 1. Patient Demographics.
Characteristic N=33 (%)
Age (years):
Median 6.9
Range 2.8–16.3
Gender:
Female 11 (33.3)
Male 22 (66.7)
Ethnicity:
Hispanic 0 (0.0)
Non-Hispanic 30 (90.9)
Unknown 3 (9.1)
Race:
Asian 1 (3.0)
African American 0 (0.0)
White 29 (87.9)
Unknown 3 (9.1)
doi:10.1371/journal.pone.0021296.t001
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CTCAE System Organ Class/Preferred Term (MedDRA) N (%) Tot. AE Grade 1 Grade 2 Grade 3
Blood/Lymphatic System Disorders: 1 (0.7)
Blood/lymphatic disorder 1 1
Ear and Labyrinth Disorders: 2 (1.5)
Hearing impaired 11
Middle ear inflammation 1 1
Gastrointestinal Disorders: 15 (10.9)
Abdominal pain 53 1 1
Constipation 11
Diarrhea 11
Vomiting 65 1
Other 22
General Disorders: 50 (36.5)
Fatigue 17 14 2 1
Fever 21 1
Flu like symptoms 43 1
Irritability 43 1
Pain 52 1 2
Other 18 8 10
Immune System Disorders: 2 (1.5)
Allergic reaction 21 1
Infections and Infestations: 24 (24.2)
Eye infection 11
Otitis media 42 2
Rhinitis infective 33
Sinusitis 22
Skin infection 11
Upper respiratory infection 1 1
Other 12 12
Injury, Poisoning and Procedural Complications: 5 (3.6)
Fall 11
Fracture 41 3
Investigations: 1 (0.7)
Neutrophil count decreased 1 1
Metabolism and nutrition disorders: 1 (0.7)
Dehydration 11
Musculoskeletal and connective tissue disorders: 2 (1.5)
Pain in extremity 11
Other 11
Nervous System Disorders: 6 (4.4)
Headache 11
Lethargy 21 1
Tremor 33
Psychiatric disorders: 4 (2.9)
Mania 11
Restlessness 11
Other 21 1
Respiratory, thoracic and mediastinal disorders: 19 (13.9)
Allergic rhinitis 11
Cough 75 2
Nasal congestion 43 1
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children $5 years and included forced vital capacity (FVC), forced
expiratory volume in 1 second (FEV1) and maximum expiratory
and inspiratory pressures (MEP, MIP). Myometry measurements
(done only in children $5 years of age) were performed three
times for right and left elbow flexion, and for right and left knee
extension, at each visit using the Lafayette Instrument MMT
System Model 01163 myometer [31,32,35–37], with the recorded
value representing the average of the three measures.
Statistical Analysis
Two baseline visits were performed with the visit closest to the
start of treatment used as the baseline evaluation for outcome
variables. Shapiro-Wilk test was used to determine if continuous
variables were normally distributed. Test-retest correlation used the
Spearman’s correlation if continuous variables were not normally
distributed. Timed tests had a restricted maximum of 3 minutes at
which time the test was ended. Since the actual maximum time to
complete the task was unknown, we considered these values as
censored. Kaplan-Meier estimates were used to compute the
summary statistics for timed tests with censored observations.
Statistical tests for change from baseline were either the Wilcoxon
signed rank test for non-normal data or the paired t-test for normal
data. Change from baseline analyses to each time point were
selected to identify if a 6 month change occurred, a 12 month
change occurred, or there was no change. The objective of this
analysis was to evaluate patterns in the data and not provide
definitive hypothesis testing; therefore, no multiplicity adjustment
was performed.
Results
Thirty-three subjects were enrolled with demographic charac-
teristics shown in Table 1. The subjects were ages 2.8 to 16.3 with
a median age of 6.9. There was an unexpected predominance of
males (n=22). Five patients did not complete the study; two
because of weight gain considered excessive by the parents (9%
increase above baseline weight in each case), one because of
gastrointestinal side effects (chronic diarrhea), one because the
parents simply changed their minds about participation, and one
because of non-compliance and psychiatric issues that predated
participation in the study and were not disclosed to investigators at
the time of screening and randomization (Figure 2). This subject
subsequently missed several study visits, was found to be non-
compliant with study medications, and therefore was withdrawn
from the study. A sixth patient missed the V1 visit but all other
data points were included in the final analysis. All of the subjects
completing the study were judged compliant by both pill counts
and by VPA levels.
Adverse Events
Adverse events (AEs) occurred in 84.8% of treated subjects
during treatment, a figure not significantly different from the side
effects encountered in the treatment and placebo group of the
Phase 1 study [32]. A detailed alphabetical listing of adverse events
with Common Terminology Criteria for Adverse Events v3.0
(CTCAE) grading is presented in Table 2. General systemic
disorders (e.g. fatigue, fever, flu-like symptoms, irritability, pain)
were the most frequent AE (36.5% of total AEs), followed by
various infections (24.2% each). Only 5 AEs (4% of total) were
classified as CTCAE Grade 3 (severe); all of these were transient
and did not require study withdrawal. Three patients developed
adverse events that led to withdrawal from the study; one had
chronic diarrhea, and two had weight gain deemed unacceptable
by the parents. Weight gain was a notable problem although
interestingly most parents and investigators did not consider this
an adverse event; 17% of the patients that completed the study
gained 20% or more of baseline weight, and one subject’s weight
increased by 49% in one patient.
Reliability of the motor function scores
The average MHFMS-Extend score at baseline was 48.3 (65.4
S.D.) with a range of 36 to 56 (median 48). The MHFMS-Extend
baseline data was skewed left (Shapiro-Wilk p=0.048). The test-
retest reliability of the MHFMS-Extend, assessed for S1-S2, was
0.93 (Table 3).
The baseline scores for the TTF, GMM component of the
MHFMS-Extend, and FMM are presented in Figure 3; all of the
measures were skewed and not normally distributed. Table 4
presents the Spearman correlation for each TTF, GMM, and
FMM scores to assess test-retest reliability. The data indicate
excellent reliability for all measures of motor function except time
to rise.
CTCAE System Organ Class/Preferred Term (MedDRA) N (%) Tot. AE Grade 1 Grade 2 Grade 3
Pneumonitis 44
Sore throat 11
Other 21 1
Skin and subcutaneous tissue disorders: 5 (3.6)
Rash maculo-papular 2 1 1
Other 33
Events are listed alphabetically with percentages indicating percent of total AEs. Grading is according to standard Common Terminology Criteria for Adverse Events
(CTCAE) grading.
doi:10.1371/journal.pone.0021296.t002
Table 2. Cont.
Table 3. Test-retest Reliability of the MHFMS-Extend S1 vs.
S2.
N Minimum Median Maximum
S1 MHFMS-Extend 30 29 48 56
S2 MHFMS-Extend 30 36 48 56
Spearman’s correlation 0.9307
doi:10.1371/journal.pone.0021296.t003
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Tables 5 and 6 illustrate the absolute scores at each time point
and the change from baseline at 6 months and 12 months for
TTF, FMM, GMM and total MHFMS-Extend. A change from
baseline score less than zero for the timed scores (i.e. a negative
number) reflects reduced time to perform the function and thus
improvement. Motor scores that have a positive change from
baseline (i.e. positive numbers) indicate improved function. There
was no significant change in function as assessed by timed test and
motor function at either 6 or 12 months.
Myometry
Because of age restrictions ($5 years) and limitations from
contractures, only 20 subjects had baseline evaluations and only 11
had a subsequent myometry assessment at 6 months. The upper
extremity and total myometry scores were normally distributed,
but the lower extremity was skewed. The baseline myometry data
and change at 6 and 12 months are shown in Figure 4. There were
no statistical differences in myometry scores over the course of the
study.
Treatment effects on electrophysiologic measures of
innervation
The results for CMAP testing at baseline and 6 and 12 months,
as well as the change from baseline to these time points, are
shown in Table 7. There was a statistically significant
improvement in CMAP negative peak amplitude at six and 12
months.
Figure 3. Box Plots of baseline values for Fine Motor Module, Gross Motor Module, and Timed Tests of Function. The Values on the
ordinate refer to seconds for the timed tests, and absolute scores for the motor modules. D indicates mean; – indicates median.
doi:10.1371/journal.pone.0021296.g003
Table 4. Reliability (Test-Related) of Timed Tests and Tests of Motor Function.
Item Score Median (1
st Baseline) Median (2
nd Baseline) Spearman Correlation p-Value
Time to 30 ft 8.5 8.0 0.9734 ,0.0001
N=28
Time to Climb 5.5 6.0 0.9190 ,0.0001
N=24
Time to Rise 9.5 8.5 0.7240 ,0.0001
N=24
Peg Time 9.0 7.0 0.8600 ,0.0001
N=29
Fine Motor 15.5 15.0 0.8272 ,0.0001
N=30
Gross Motor 8.0 9.5 0.9267 ,0.0001
N=30
doi:10.1371/journal.pone.0021296.t004
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assessments
Quality of life was measured using the PedsQL
TM, both as
reported by parent-proxy and, where appropriate, by the subjects
themselves. The baseline self-reported PedsQL
TM data and
change at six and 12 months are shown in Table 8. According
to the child’s own assessment, there was a deterioration of physical
functioning at 12 months (p=0.008). There was no associated
change in any domain of quality of life by parent assessment (data
not shown).
Pulmonary Function Testing
The PFT did not depart from normality at baseline. None of the
PFT parameters changed significantly from baseline at six months
(data not shown). At one year, only FVC (p=0.04) and FEV1
values (p=0.009) had significantly improved, a change that must
be interpreted with caution, since FVC normally increases
normally with age [38].
VPA Trough Levels
Table 9 presents VPA trough levels. On average, subjects
achieved the desired trough level of 50, providing strong evidence
of compliance with the regimen. There were no associations with
VPA levels and timed tests or MHFMS-Extend.
mRNA Assay
The baseline and change from baseline at 6 and 12 months for
flSMN and D7 SMN transcripts are shown in Table 10. There was
no significant change in SMN transcript level from baseline at
either time point.
Discussion
The combination of VPA and L-carnitine did not lead to
improvement in the primary outcome variables under the
conditions defined by this protocol in an ambulatory population
of children with SMA. The primary outcome measure of the
MHFMS-Extend proved reliable and practical, and experience
with many of the secondary outcome variables employed in this
study will prove useful in the design of future clinical trials in this
group. These results in this open-label trial further establish the
reliability of these measures for clinical trials. The combination of
VPA and L-carnitine proved safe at the doses used. Among the
secondary outcomes, myometry measured strength and quality of
Table 5. Timed Tests and Motor Function; 6 Month Observed
Values and Change from Baseline.
Item 6 Month Value Change from Baseline
Time to 30 ft
N2 6 2 6
Median 7.5 0
Range 3–39 25–17
Time to Climb
N2 5 2 3
Median 7 21
Range 2–47 226–2
Time to Rise
N2 5 2 5
Median 9 0
Range 2–55 2146–29
Peg Time
N2 7 2 6
Median 8 0
Range 4–17 24–4
Fine Motor Score
N2 8 2 8
Median 15.5 0
Range 0–16 210–15
Gross Motor Score
N2 8 2 8
Median 8 1
Range 0–16 25–3
MHFMS-Extend
N2 8 2 8
Median 48 1
Range 32–56 211–7
doi:10.1371/journal.pone.0021296.t005
Table 6. Timed Tests and Motor Function 12 Month;
Observed Value and Change from Baseline.
Item 12 Month Value Change from Baseline
Time to 30 ft:
N2 5 2 4
Median 7 0
Range 3–180 23–49
Time to Climb:
N2 2 2 1
Median 6.5 0
Range 2–180 251–7
Time to Rise:
N2 2 2 2
Median 8 0
Range 2–180 212–45
Peg Time:
N2 6 2 5
Median 8.5 0
Range 4–18 29–3
Fine Motor Score:
N2 7 2 7
Median 15 0
Range 0–16 216–15
Gross Motor Score:
N2 7 2 7
Median 8 0
Range 0–16 25–3
MHFMS-Extend:
N2 7 2 7
Median 48 0
Range 30–56 213–4
doi:10.1371/journal.pone.0021296.t006
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of pulmonary function (FVC and FEV1) did show significant
improvement at one year, these changes are within the range
expected with normal growth in children with SMA, for which
natural history data are limited; these findings are therefore
difficult to interpret especially given the other negative results.
CMAP amplitude did improve at six and 12 months, but without a
corresponding increase in function, the significance of this finding
is difficult to interpret. However, it is possible that a modest
biologic effect on sprouting was negated by weight gain, voiding
any ultimate impact on motor functions. The lack of a significant
change in relative SMN transcript levels after 6 and 12 months is
consistent with the absence of a VPA effect on clinical measures. A
more effective treatment is needed before we can adequately assess
the value of quantifying SMN transcripts in whole blood as a
potential surrogate marker of drug response.
We did not observe any clinical or laboratory evidence of
serious hematologic or hepatic toxicity in this study, but four
patients dropped out due to medication side effects. Excessive
weight gain was a common adverse event that was almost
certainly compounded by treatment with VPA. However,
children and young adults with ambulatory SMA who are not
on VPA are also prone to excessive weight gain with age, and
this needs to be carefully considered in the design of future
clinical trials, since this clearly plays a role in functional decline
with age in some ambulatory children. DEXA scanning revealed
that the associated weight gain was due largely to an increase in
total body fat mass in the absence of an increase in lean mass
(data not shown), an obvious concern in a population already
predisposed to higher fat mass indices or frank obesity [38,39].
Although considerable in some patients in this study, however,
the weight gain did not appear to have deleterious effects on
f u n c t i o n i n gi nt h i sp o p u l a t i o ni nt h ec o n t e x to ft h i ss t u d yo v e r
the time period examined.
Both this and the companion study on non-ambulatory
children ages 2 to 8 failed to demonstrate improvement in the
primary outcome variable [31]. The choices of inclusion criteria,
dose, duration, and outcome variables were necessarily based on
our best hypotheses given the lack of previous studies with VPA
in children with SMA, and limited experience in rigorous clinical
studies in this population. However, the experience gained in this
trial will be invaluable to the design of future trials. Whether a
treatment effect of VPA exists in SMA under specific circum-
stances, and can be demonstrated in trials in other targeted
groups remains possible and hints of this are suggested by
subgroup analysis of the non-ambulatory children. At least in this
trial, however, any modest biologic effects were likely negated by
weight gain in terms of any ultimate effect on motor function.
Studies on the efficacy of VPA in ambulatory adults and a
preliminary study of VPA safety in severely affected infants are
Figure 4. Box plot of baseline myometry data (column 1) and change from baseline (CFB) at 6 months (column 2) and 12 months
(column 3). LE=lower extremity; TE=total myometry; UE=upper extremity. D indicates mean; – indicates median.
doi:10.1371/journal.pone.0021296.g004
Table 7. Change from Baseline (CFB) at 6 and 12 Months in
Compound Motor Action Potential (CMAP).
Baseline
CFB 6
Months CFB 12 Months
Characteristic N=24 N=20 N=13
CMAP Amplitude:
Median 5.30 0.70 1.66
Range 1.20–10.42 20.80–3.00 21.40–4.55
Shapiro-Wilk p=0.2928
Paired t-test p=0.0022 p=0.0012
doi:10.1371/journal.pone.0021296.t007
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tion to guide us regarding the most appropriate clinical trial
designs and choice of primary outcome measures as more potent
therapies become available.
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